FDA Approves Roche’s Susvimo for Diabetic Macular Edema

Susvimo, Roche’s refillable eye implant, offers continuous treatment for diabetic macular edema with as few as two treatments per year, improving vision.

New Data Shows Gazyva’s Superiority in Lupus Nephritis

The REGENCY trial confirms Gazyva's effectiveness in treating lupus nephritis, with nearly half of patients achieving complete renal response (CRR).

Thermo Fisher Partners with X-ELIO for Renewable Energy

Thermo Fisher accelerates its renewable electricity goal in Europe with a 10-year solar power agreement, reducing emissions across the healthcare supply chain.

Pfizer’s BRAFTOVI Improves Survival in Phase 3 Trial

Pfizer's BRAFTOVI combination shows significant improvements in survival for metastatic colorectal cancer patients with BRAF V600E mutation in Phase 3 trial.

EYLEA HD® Phase 3 Trial Yields Promising Results

EYLEA HD® (aflibercept) 8 mg demonstrates improved vision with fewer injections in patients with macular edema following retinal vein occlusion.